The main aim of the current study will be to determine the metabolic fate of dietary protein. More specifically, the main aim is to assess the incorporation of protein-derived amino acids in a wide variety of organ tissues in vivo in humans.
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
Eiwitmetabolisme
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameter is the incorporation of dietary protein-derived amino
acids in different organ tissues, expressed as % of ingested amount of protein.
Secondary outcome
We expect that in most surgical procedures, muscle tissue will be removed as
part of the standard surgical procedure. The second study parameter is the
incorporation of dietary protein-derived amino acids in muscle tissue,
expressed as % of ingested protein. In case no muscle tissue will be removed as
part of the standard surgical procedure, this outcome will not be calculated
for that specific participant.
Background summary
It has been well-established that ~95% of high-quality protein (i.e. milk
protein) is digested and absorbed, with the remaining ~5% being excreted in
feces. Following absorption, ~10% of dietary protein-derived amino acids are
incorporated in skeletal muscle tissue and ~10% is accounted for by protein
oxidation. However, the metabolic fate of the remaining ~75% of dietary
protein-derived amino acids has not yet been determined. Presumably, these
amino acids are incorporated into other tissues such as the intestine, liver,
heart, skin, and brain. However, direct evidence for dietary protein-derived
amino acid incorporation is lacking for most tissues. Therefore, the objective
of this project is to assess the metabolic fate of ingested dietary
protein-derived amino acids. Specifically, we will for the first time quantify
the incorporation of dietary protein-derived amino acids in a wide variety of
organ tissues in vivo in humans. We hypothesize that dietary protein-derived
amino acids are incorporated in all organ tissues, with a relatively larger
incorporation in tissues with higher protein turnover rates such as the gut and
brain.
Study objective
The main aim of the current study will be to determine the metabolic fate of
dietary protein. More specifically, the main aim is to assess the incorporation
of protein-derived amino acids in a wide variety of organ tissues in vivo in
humans.
Study design
The present study confers to a single-arm prospective study in which all
participants receive the same treatment prior to planned surgery that involves
(partial) resection of organ tissue.
Intervention
Participants will consume 40 grams of intrinsically L-[1-13C]-phenylalanine
labelled milk protein, dissolved in 400 mL water on the evening before planned
surgery.
Study burden and risks
The burden and risks associated with participation are small. The nutritional
intervention of providing 40 grams of dietary protein before sleep on the
evening prior to surgery does not pose any risks. Intrinsically labelled milk
protein is physiologically identical to regular milk protein, is considered
safe and has been applied extensively within our lab and by others. Collection
of tissue samples during planned surgery does not bring any additional risks.
Tissue collection will only be performed on organ tissue that will be removed
as part of the regular surgical procedure.
Universiteitssingel 40
Maastricht 6229ER
NL
Universiteitssingel 40
Maastricht 6229ER
NL
Listed location countries
Age
Inclusion criteria
Adults
1. >= 18 years old
2. Planned surgery that involves the (partial) resection of organ tissue
3. 18.5 <= BMI <= 30 kg/m2
4. Written informed consent
Children
1. >= 8 years old and <= 14 years old
2. Planned surgery that involves the (partial) resection of organ tissue
3. 14 <= BMI <= 30 kg/m2
4. Written informed consent by parents
Exclusion criteria
1. Lactose intolerant or allergy to milk proteins
2. Recent (<12 months) participation in L-[1-13C-phenylalanine] tracer studies
3. Cachexia (loss of 5% or more of body weight over the preceding 6 months)
4. Receiving enteral or parenteral nutrition
5. Score of 2 or more on the Malnutrition Universal Screening Tool (MUST)
6. Co-morbidities and neuromuscular disorders of the lower limbs severely
interacting with mobility with limited or no opportunity for improvement (e.g.
cerebral palsy);
7. Peripheral arterial disease Fontaine III or IV
8. Chronic obstructive pulmonary disease (COPD) GOLD III or IV
9. Use of systemic steroids in the past four weeks, other than indicated for
the specific type of surgery
10. Use anti-inflammatory biologicals (e.g. TNF-alfa blockers) in the past four
weeks
11. Phenylketonuria (PKU)
12. Surgical intervention in the past four weeks
13. Insulin dependent diabetes mellitus
14. Total parenteral nutrition at day of surgery
15. Pregnancy
16. Neoadjuvant chemo- or radiotherapy in the past four weeks
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL87518.000.24 |